{"entity":{"id":"durie-salmon","kind":"term","name":"Durie-Salmon staging of myeloma","aka":["Durie-Salmon","Durie-Salmon stage","Durie-Salmon staging"],"tldr":"Durie-Salmon staging estimated how much myeloma is in the body from bone damage, haemoglobin, calcium and the abnormal protein; ISS and R-ISS have replaced it, but older reports and trials still use it.","summary":"Durie and Salmon (Cancer 1975) measured myeloma cell mass in 71 patients from the production and turnover of the monoclonal protein and found it could be predicted from four features: the extent of bone lesions, haemoglobin, serum calcium, and the M-protein level in blood and urine. They built a clinical staging system with three tumour cell mass levels, which correlated with response and survival. The census notes it is superseded by ISS and R-ISS but still appears on reports and in older trial eligibility.","asOf":"2026-11-04","links":[{"label":"Durie and Salmon, A clinical staging system for multiple myeloma (Cancer 1975)","url":"https://doi.org/10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u"}],"tags":[],"related":["r-iss","imwg-response-criteria","staging-systems"],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical"},"route":"/terms/durie-salmon/","neighbours":{"term":[{"id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/"},{"id":"imwg-response-criteria","kind":"term","name":"IMWG response criteria for myeloma (2016, with MRD)","route":"/terms/imwg-response-criteria/"},{"id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/"}],"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}]}}